Identifying biomarkers for latent tuberculosis infection
Precision immunoprofiling to reveal diagnostic biomarkers of latent TB infection
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10471266
This study is working on better ways to find out who is at the highest risk of developing active tuberculosis from a hidden infection, so that those people can get the right treatment to stay healthy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10471266 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the diagnosis of latent tuberculosis infection (LTBI) by developing new methods to identify patients at the highest risk of reactivation. It aims to combine advanced biomarker detection techniques with bioinformatics to create a more personalized approach to monitoring immune responses. By doing so, the research seeks to enhance the accuracy of LTBI diagnosis beyond current methods, which often fail to predict reactivation risk effectively. Patients who are identified as high-risk could then receive targeted treatment to prevent the progression to active tuberculosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with latent tuberculosis infection, particularly those who may be at higher risk of reactivation.
Not a fit: Patients who do not have latent tuberculosis infection or those with active tuberculosis will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses and targeted treatments for patients with latent tuberculosis infection, potentially reducing the risk of developing active TB.
How similar studies have performed: Previous research has shown promise in using advanced biomarker detection and bioinformatics for improving diagnostic accuracy in other infectious diseases, suggesting potential success for this novel approach.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BAILEY, RYAN C — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: BAILEY, RYAN C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.